• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The journal of sexual medicine >Evaluation of patient expectations and treatment satisfaction after 1-year tadalafil therapy for erectile dysfunction: the DETECT study.
【24h】

Evaluation of patient expectations and treatment satisfaction after 1-year tadalafil therapy for erectile dysfunction: the DETECT study.

机译：他达拉非治疗勃起功能障碍1年后患者期望值和治疗满意度的评估：DETECT研究。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

INTRODUCTION: Erectile dysfunction (ED) is a self-reported condition and satisfaction with sexual performance is individual, subjective, and multi-factorial. Treatment success depends on several outcomes. Tadalafil is a long-acting, selective inhibitor of phosphodiesterase 5 that has been shown to be effective at treating men with ED. AIM: To investigate patient's ED treatment expectations at baseline; patient satisfaction with tadalafil treatment after 12 months; factors associated with satisfaction; and effect of early tadalafil treatment satisfaction on tadalafil continuation at 12 months. METHODS: The Determinants of Continued Use of Tadalafil study is a 12-month, prospective, pan-European, noninterventional, observational study, which enrolled 1,900 patients with ED wishing to initiate or change their treatment to tadalafil. Assessments were made on predefined treatment outcomes in a routine clinical setting. MAIN OUTCOME MEASURES: International Index of Erectile Function-erectile function domain scores (at baseline, 1, 6, and 12 month visit), ED Inventory of Treatment Satisfaction (EDITS) scores (after 1, 6, and 12 months), and patient expectation questionnaire (at baseline visit) were analyzed for these patients. RESULTS: Data were available from 1,567 patients (82%) after 12 months, with similar baseline characteristics as the initial cohort. Treatment expectations identified as important included: erection hardness and ability to maintain erection through intercourse completion (>92% of patients); confidence, partner satisfaction, and naturalness (>84% of patients); rapid effect and long duration of treatment (>75% of patients). Continued tadalafil use from 1,319 (84%) patients at 12 months were reported. Total EDITS scores for those continuing treatment was 85.9 (95% CI: 85.1-86.7). Increased satisfaction was associated with higher effectiveness, number of sexual attempts, partner support, good relationships, and good drug tolerance. Treatment satisfaction at 1 month was best predictive of treatment continuation at 12 months. CONCLUSIONS: Eighty-four percent of patients reported continued use of tadalafil after 12 months. High satisfaction after first month of treatment was the best predictor of treatment continuation.
机译：简介：勃起功能障碍（ED）是一种自我报告的疾病，对性行为的满意度是个体的，主观的和多因素的。治疗的成功取决于几个结果。他达拉非是磷酸二酯酶5的一种长效选择性抑制剂，已显示对治疗ED男性有效。目的：调查基线时患者对ED治疗的期望; 12个月后患者对他达拉非治疗的满意度;与满意度有关的因素;他达拉非早期治疗满意度对他达拉非持续治疗12个月的影响。方法：持续使用他达拉非的决定因素研究是一项为期12个月的前瞻性，泛欧洲，非介入性观察性研究，该研究招募了1,900名希望开始或将其改为他达拉非的ED患者。在常规临床环境中对预定义的治疗结果进行评估。主要观察指标：勃起功能-勃起功能域评分的国际索引（在基线，就诊1、6和12个月时），ED治疗满意度清单（编辑）评分（在1、6和12个月后）和患者对这些患者的预期问卷（基线访视）进行了分析。结果：12个月后有1567名患者（82％）获得了数据，其基线特征与最初队列相似。被确定为重要的治疗期望包括：勃起硬度和通过性交完成维持勃起的能力（> 92％的患者）;信心，伴侣满意度和自然度（> 84％的患者）;效果快，治疗时间长（> 75％的患者）。据报道在12个月时有1,319名患者（84％）继续使用他达拉非。那些持续治疗的总EDITS得分为85.9（95％CI：85.1-86.7）。满足感的提高与有效性，性尝试次数，伴侣支持，良好的人际关系和良好的药物耐受性有关。 1个月的治疗满意度是12个月治疗持续时间的最佳预测。结论：84％的患者报告他达拉非在12个月后继续使用。治疗第一个月后的高满意度是治疗持续时间的最佳预测指标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号